Apexomic

Executive Summary

Apexomic is a UK-based biotechnology services company founded in 2019 that leverages artificial intelligence and machine learning to transform complex multi-omics and biological data into actionable insights for drug discovery and asset development. By providing expert data analytics to biologists and pharmaceutical innovators, the company accelerates R&D efforts, enabling clients to make faster, data-driven decisions. Its platform addresses the growing need for efficient analysis of high-dimensional biological datasets, positioning Apexomic as a key enabler in the precision medicine and AI-driven drug discovery landscape. While still private and early-stage, the company's focus on actionable analytics and its UK location in a thriving life sciences hub suggest potential for steady growth as it expands its client base and service offerings.

Upcoming Catalysts (preview)

• Q4 2026Major pharma partnership announcement60% success
• Q1 2027Launch of new AI-driven multi-omics analytics module70% success
• Q2 2027Series A funding round closing50% success